EP0910358A1 - Phenyl derivatives useful as blockers of chloride channels - Google Patents

Phenyl derivatives useful as blockers of chloride channels

Info

Publication number
EP0910358A1
EP0910358A1 EP97924020A EP97924020A EP0910358A1 EP 0910358 A1 EP0910358 A1 EP 0910358A1 EP 97924020 A EP97924020 A EP 97924020A EP 97924020 A EP97924020 A EP 97924020A EP 0910358 A1 EP0910358 A1 EP 0910358A1
Authority
EP
European Patent Office
Prior art keywords
trifluoromethyl
alkyl
aryl
hydroxy
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97924020A
Other languages
German (de)
French (fr)
Inventor
Palle Christophersen
Ove Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of EP0910358A1 publication Critical patent/EP0910358A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups

Definitions

  • the present invention relates to phenyl derivatives which are valuable blockers of chloride channels and as such useful for the treatment of sickle cell anaemia, brain oedema following ischaemia or tumours, diahreea, hypertension (diuretic) and for the reduction of the intraocular pressure for the treatment of disorders such as glaucoma.
  • the compounds of the invention may also be useful in the treatment of allergic or inflammatory conditions and for the promotion of wound healing.
  • Chloride channels serve a wide variety of specific cellular functions and contribute to the normal function of skeletal and smooth muscle cells. Blockers of chloride channels are known to be useful in the treatment of brain oedema following ischaemia or tumours, diahreea, hypertension (diuretic) and for the reduction of the intraocular pressure in disorders such as glaucoma.
  • Sickle cell anaemia and the existence of sickle haemoglobin was the first genetic disease to be understood at the molecular level.
  • the genetic defect underlying sickle cell anaemia causes the substitution of a single amino acid resulting in a mutant haemoglobin, sickle haemoglobin.
  • sickle cell disease is anaemia and painful ischaemic crises due to occlusion of the microcirculation by deformed erythrocytes (sickle cells).
  • the primary cause of sickle erythrocyte deformation and distortion (or sickling) is a reversible polymerisation and gelation of sickle haemoglobin induced at the low oxygen tensions prevalent in metabolically active tissues.
  • Sickle cells are also characterised by an enhanced cation permeability, resulting in cation depletion and cellular dehydration. Since the delay time for the polymerisation has been described as an extremely steep function of the sickle haemoglobin concentration itself, any decrease in cell volume will greatly increase the probability of sickling and thereby of vessel occlusion.
  • the compounds according to the invention are valuable blockers of chloride channels as determined by concomitant measurements of conductive netfluxes of chloride and membrane potentials in suspensions of erythrocytes, and the compounds are therefore predicted to be useful in the treatment of ailments responsive to the blockade of chloride channels.
  • US patent No. 4.889.612 describes Calixarene derivatives and their use as chloride channel blockers.
  • US patent No. 4.994.493 describes certain 5-nitrobenzoic acid derivatives and their use in the treatment of cerebral oedema.
  • WO 96/16647 describes the use of chloride channel blockers for the reduction of the intraocular pressure and specifically the use of chloride channel blockers for the treatment of glaucoma.
  • Still another object of the present invention is to provide a method of treating disorders or diseases responsive to the blockade of chloride channels, such as for example brain oedema following ischaemia or tumours, diahreea, hypertension (diuretic), glaucoma and in particular sickle-cell anaemia.
  • a further object of the present invention is to provide a method for the treatment of allergic or inflammatory conditions and for the promotion of wound healing.
  • the invention then comprises, inter alia, alone or in combination:
  • R 2 , R 3 , R 4 and R 5 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl and heteroaryl groups may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; and heteroaryl, or R 3 and R 4 or R 4 and R 5 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially
  • X is -NH-, -CH 2 -NH-, -SO 2 -NH-, or CH 2 ;
  • R 11 , R 12 , R 13 , R 14 and R 15 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalky, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or one of R 11 and R 12 , R 12 and R 13 , R 13 and R 14 or R 14 and R 15 together form a fused 4 to 7 membered carbo
  • a compound as above for the preparation of a medicament for the treatment of sickle-cell anaemia, brain oedema following ischaemia, or tumours, diahreea, hypertension (diuretic) and glaucoma; the use of a compound as above for the preparation of a medicament for the treatment of allergic or inflammatory conditions and ulcers;
  • a method for the treatment of a disorder or disease of a living animal body including a human, which disorder or disease is responsive to the blockade of chloride channels, comprising administering to a living animal body in need thereof a therapeutically effective amount of a compound having the formula
  • R 2 , R 3 , R 4 and R 5 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy; cyano, nitro and amino; or R 3 and R 4 or R 4 and R 5 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other
  • X is -NH-, -CH 2 -NH-, -SO 2 -NH-, or -CH 2 -;
  • R 11 , R 12 , R 13 , R 14 and R 15 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or one of R 11 and R 12 , R 12 and R 13 , R 13 and R 14 or R 14 and R 15 together form a fused 4 to 7 membered carb
  • a method for the treatment of a disorder or disease of a living animal body which disorder or disease is sickle-cell anaemia, brain oedema following ischaemia, or tumours, diahreea, hypertension (diuretic) or glaucoma comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a compound as defined above; and
  • a method for the treatment of a disorder or disease of a living animal body which disorder or disease is allergic or inflammatory conditions or ulcers comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a compound as above.
  • Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, nitrate, perchlorate, sulfate, citrate, lactate, tartrate, maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, glycollate, toluene-p-sulphonate, formate, malonate, naphthalene-2- sulphonate, salicylate and the acetate.
  • Such salts are formed by procedures well known in the art.
  • acids such as oxalic acid, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Halogen is fluorine, chlorine, bromine or iodine.
  • Alkyl means a straight chain or branched chain of one to six carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl; methyl, ethyl, propyl and isopropyl are preferred groups.
  • Cycloalkyl means cyclic alkyl of three to seven carbon atoms, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
  • Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.
  • Alkenyl means a group of from two to six carbon atoms, including at least one double bond, for example, but not limited to ethenyl, 1 ,2- or 2,3-propenyl, 1 ,2-, 2,3-, or 3,4-butenyl.
  • Alkynyl means a group of from two to six carbon atoms, including at least one triple bond, for example, but not limited to ethynyl, 1 ,2-, 2,3-propynyl, 1 ,2-, 2,3- or 3,4- butynyl.
  • Alkoxy is O-alkyl, wherein alkyl is as defined above.
  • Amino is NH 2 or NH-alkyl or N-(alkyl) 2 , wherein alkyl is as defined above.
  • Heteroaryl is a 5- or 6-membered heterocyclic monocyclic group.
  • Such a monocyclic heteroaryl group includes, for example, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3- yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl, 1 ,2,4- thiadiazol-3-yl, 1 ,2,4-thiadiazol-5-yl, 1 ,2,5-oxadiazol-3-yl, 1 ,2,5-oxadiazol-4-yl, 1 ,2,5-thiadia
  • Aryl means an aromatic group such as phenyl or naphtyl.
  • Aralkyl means arylalkyl wherein aryl and alkyl is as defined above, meaning for example benzyl or phenethyl.
  • I.p. means intraperetoneally, which is a well known route of administration.
  • P.O. means perorai, which is a well known route of administration.
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds ot the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example.
  • the compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present invention with an optically active chloroformate or the like.
  • an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid
  • the compounds of the invention may be prepared in numerous ways.
  • the compounds of the invention and their pharmaceutically acceptable derivatives may thus be prepared by any method known in the art for the preparation of compounds of analogous structure, and as shown in the representative examples which follow.
  • the compounds of the present invention are potent blockers of chloride channels in normal as well as sickle cell erythrocytes.
  • the ability of the compounds to block the erythrocyte chloride channels could not be demonstrated by classical electrophysiological measurements such as patch clamping, since the channel unit conductance is below the detection limit of these techniques.
  • a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.
  • the invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub ⁇ cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • compositions and unit dosages thereof may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • Formulations containing ten (10) milligrams of active ingredient or, more broadly, 0.1 to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as admixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrroUdone (PVP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrroUdone (PVP).
  • PVP polyvinylpyrroUdone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
  • the compounds of the present invention are, due to their potent chloride channel blocking activity, useful in the treatment of sickle cell anaemia, brain oedema following ischaemia or tumors, diahreea, and hypertension (diuretic) as well as other disorders responsive to the blockade of chloride channels.
  • the compounds of the invention may also be useful in the treatment of allergic and inflammatory conditions, for the promotion of wound healing and the treatment of ulcers.
  • the compounds of the present invention may accordingly be administered to a living animal body, including a human, in need of treatment, alleviation, or elimination of an indication associated with or responsive to chloride channel blocking activity. This includes especially sickle cell anaemia, brain oedema following ischaemia or tumors, diahreea, and hypertension (diuretic).
  • Suitable dosage range are 0.1-500 milligrams daily, and especially 10-70 milligrams daily, administered once or twice a day, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • the following examples will illustrate the invention further, however, they are not to be construed as limiting.
  • M.p. 199-200°C N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl) urea.
  • N-(3-(trifluoromethyl)phenyl)-N'-(3-hydroxy-2-naphthyl) urea M.p. 184-188°C (dec), N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-1-naphthyl) urea.
  • M.p. 169-171 °C N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-6-nitrophenyl) urea.
  • N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-4-nitrophenyl) urea (1.00 g, 2.9 mmol) was subjected to catalytic reduction in tetrahydrofuran (50 ml) using 5% palladium on carbon (0.20 g). The reaction mixture was filtered through a path of celite. Evaporation of the filtrate and subsequent recrystallization of the crude product from methanol/water 1 :1 (50 ml) afforded the title compound. 0.68 g (75%) of the title compound was isolated. M.p. 200-202°C.
  • N-(3-carboxyphenyl)-N'-(2-methoxy-5-chlorophenyl) urea (3.00 g, 9.4 mmol) was suspended in methanol (100 ml). Concentrated sulfuric acid (1.0 ml) was added and the reaction was heated at reflux for 6 hours. The reaction mixture was poured into cold (0°C) water (600 ml). Filtration of the suspension afforded the crude product. The crude product was purified by column chromatography on silica using dichloromethane/ethyl acetate 19:1 as eluent. 2.35 g of the title compound was isolated.
  • N-(3-carbamoylphenyl)-N'-(2-methoxy-5-chlorophenyl) urea N-(3-(trifluoromethoxy)phenyl)-N'-(2-methoxy-5-chlorophenyl) urea
  • N-(3-methylphenyl)-N'-(2-methoxy-5-chlorophenyl) urea N-(3-hydroxyphenyl)-N'-(2-methoxy-5-chlorophenyl) urea
  • N-(3-nitrophenyl)-N'-(2-methoxy-5-chlorophenyl) urea N-(3-carboxyphenyl)-N'-(2-methoxy-5-chlorophenyl) urea.
  • N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorobenzyl) urea M.p. 56-66°C
  • N-(3-(trifluoromethyl)phenyl)-N'-(2,3-dihydroxybenzyl) urea M.p. 159-161 °C
  • N-(2-hydroxy-5-chlorophenyl)-3-(trifluoromethyl)phenylacetic amide M.p. 148-153°C
  • N-(3, 5-dichlorophenyl)-N'-(2-hydroxy-5-(trifluoromethyl)phenyl) urea M.p.

Abstract

The present invention relates to a method for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels, comprising administering to a living animal body in need thereof a therapeutically effective amount of a compound having formula (I) or a pharmaceutically acceptable salt thereof wherein R?2, R3, R4 and R5¿ are each independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or R?3 and R4 or R4 and R5¿ together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R?2, R3, R4 and R5¿ is as defined above; Y is -CO-, -CS-, -SO¿2?-, or -C(=N-R?8¿)-, wherein R8 is hydrogen, alkyl, or cyano; X is -NH-, -CH¿2?-NH-, -SO2-NH-, or -CH2-; Z is -NR?6¿-, -O-, -CH=CH-, -N=CH-, -CH=N-, or -NR6-CH2-, wherein R6 is hydrogen, or alkyl; R?11, R12, R13, R14 and R15¿ are each independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or one of R?11 and R12, R12 and R13, R13 and R14 or R14 and R15¿ together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R?11, R12, R13, R14 and R15¿ is as defined above.

Description

Phenyl derivatives useful as blockers of chloride channels
The present invention relates to phenyl derivatives which are valuable blockers of chloride channels and as such useful for the treatment of sickle cell anaemia, brain oedema following ischaemia or tumours, diahreea, hypertension (diuretic) and for the reduction of the intraocular pressure for the treatment of disorders such as glaucoma. The compounds of the invention may also be useful in the treatment of allergic or inflammatory conditions and for the promotion of wound healing.
Background
Chloride channels serve a wide variety of specific cellular functions and contribute to the normal function of skeletal and smooth muscle cells. Blockers of chloride channels are known to be useful in the treatment of brain oedema following ischaemia or tumours, diahreea, hypertension (diuretic) and for the reduction of the intraocular pressure in disorders such as glaucoma.
Sickle cell anaemia and the existence of sickle haemoglobin was the first genetic disease to be understood at the molecular level. The genetic defect underlying sickle cell anaemia causes the substitution of a single amino acid resulting in a mutant haemoglobin, sickle haemoglobin.
The physical manifestations of sickle cell disease is anaemia and painful ischaemic crises due to occlusion of the microcirculation by deformed erythrocytes (sickle cells). The primary cause of sickle erythrocyte deformation and distortion (or sickling) is a reversible polymerisation and gelation of sickle haemoglobin induced at the low oxygen tensions prevalent in metabolically active tissues. Sickle cells are also characterised by an enhanced cation permeability, resulting in cation depletion and cellular dehydration. Since the delay time for the polymerisation has been described as an extremely steep function of the sickle haemoglobin concentration itself, any decrease in cell volume will greatly increase the probability of sickling and thereby of vessel occlusion. Compounds which blocks the deoxygenation induced salt and volume (water) loss may delay the sickling process enough to avoid occlusion upon the passage of the sickle erythrocyte through metabolically active tissue. It has been estimated that a delay time of only 10 sec may suffice. Several membrane ion channels and transporters present in normal erythrocytes has been suggested to participate in the altered membrane permeabilities of sickle cells. The favoured hypothesis has been stimulation of the Ca2+-activated K+-channel and several blockers of this channel has been suggested as therapeutic agents for the treatment of sickle-cell anaemia ( Effects of Cetiedil on Monovalent Cation Permeability in the Erythrocyte: An explanation for the Efficacy of Cetiedil in the treatment of Sickle Cell Anaemia, Berkowitz, L. R., Orringer, E. P., Blood cells, (283- 288 (1982) and US patent No. 5.273.992).
Since, K+ efflux through a K-channel must be followed by an equal efflux of Cl" to maintain electroneutrality, blockade of erythrocyte chloride channels are predicted to be as effective as blocking the K-channels itself. An advantage to the use of chloride channel blockers is that salt loss which may occur due to activation of unknown K-channel types will indirectly be blocked too.
The compounds according to the invention are valuable blockers of chloride channels as determined by concomitant measurements of conductive netfluxes of chloride and membrane potentials in suspensions of erythrocytes, and the compounds are therefore predicted to be useful in the treatment of ailments responsive to the blockade of chloride channels.
The use of blockers of chloride channels for the treatment of sickle-cell anaemia form a new therapeutic approach.
Several chloride channel blockers and the use thereof have already been described in the technical literature:
Pflϋgers Arch (1986), 407 (suppl. 2), pages 128-141 describes several compounds with chloride channel blocking activity. A very potent compound described herein is 5-nitro-2-(3-phenyipropylamino)benzoic acid. The reference do not disclose the use of chloride channel blockers for the treatment of sickle cell anaemia.
US patent No. 4.889.612 describes Calixarene derivatives and their use as chloride channel blockers. US patent No. 4.994.493 describes certain 5-nitrobenzoic acid derivatives and their use in the treatment of cerebral oedema.
WO 96/16647 describes the use of chloride channel blockers for the reduction of the intraocular pressure and specifically the use of chloride channel blockers for the treatment of glaucoma.
Objects of the Invention
It is an object of the present invention to provide a series of phenyl derivatives and pharmaceutically acceptable salts thereof which are useful for the preparation of a medicament for the treatment of disorders or diseases responsive to the blockade of chloride channels.
Still another object of the present invention is to provide a method of treating disorders or diseases responsive to the blockade of chloride channels, such as for example brain oedema following ischaemia or tumours, diahreea, hypertension (diuretic), glaucoma and in particular sickle-cell anaemia. A further object of the present invention is to provide a method for the treatment of allergic or inflammatory conditions and for the promotion of wound healing.
Summary of the Invention
The invention then comprises, inter alia, alone or in combination:
The use of a compound having the formula
or a pharmaceutically acceptable salt thereof
wherein R2, R3, R4 and R5 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl and heteroaryl groups may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; and heteroaryl, or R3 and R4 or R4 and R5 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R2, R3, R4 and R5 is as defined above;
Y is -CO-, -CS-, -SO2-, or -C(=N-R8)-, wherein R8 is hydrogen, alkyl, or cyano;
X is -NH-, -CH2-NH-, -SO2-NH-, or CH2;
Z is- NR6-, -O-, -CH=CH-, -N=CH-, -CH=N-t or -NR6-CH2- ; wherein R6 is hydrogen, or alkyl;
and
R11, R12, R13, R14 and R15are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalky, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or one of R11 and R12, R12 and R13, R13 and R14or R14 and R15 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R11, R12, R13, R14 and R15 is as defined above, for the preparation of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels;
the use of a compound as above for the preparation of a medicament for the treatment of sickle-cell anaemia, brain oedema following ischaemia, or tumours, diahreea, hypertension (diuretic) and glaucoma; the use of a compound as above for the preparation of a medicament for the treatment of allergic or inflammatory conditions and ulcers;
a method for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels, comprising administering to a living animal body in need thereof a therapeutically effective amount of a compound having the formula
or a pharmaceutically acceptable salt thereof
wherein
R2, R3, R4and R5 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy; cyano, nitro and amino; or R3and R4 or R4 and R5 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R2, R3, R4 and R5 is as defined above;
Y is -CO-, -CS-, -SO2-, or -C(=N-R8)-, wherein R8 is hydrogen, alkyl, or cyano;
X is -NH-, -CH2-NH-, -SO2-NH-, or -CH2-;
Z is NR6, O, -CH=CH-, -N=CH-, -CH=N-, or -NR6-CH2-; wherein R6 is hydrogen, or alkyl;
R11, R12, R13, R14and R15are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or one of R11 and R12, R12 and R13, R13and R14 or R14 and R15 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R11, R12, R13, R14and R15 is as defined above;
a method for the treatment of a disorder or disease of a living animal body which disorder or disease is sickle-cell anaemia, brain oedema following ischaemia, or tumours, diahreea, hypertension (diuretic) or glaucoma comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a compound as defined above; and
a method for the treatment of a disorder or disease of a living animal body which disorder or disease is allergic or inflammatory conditions or ulcers comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a compound as above.
Examples of pharmaceutically acceptable addition salts include inorganic and organic acid addition salts such as the hydrochloride, hydrobromide, phosphate, nitrate, perchlorate, sulfate, citrate, lactate, tartrate, maleate, fumarate, mandelate, benzoate, ascorbate, cinnamate, benzenesulfonate, methanesulfonate, stearate, succinate, glutamate, glycollate, toluene-p-sulphonate, formate, malonate, naphthalene-2- sulphonate, salicylate and the acetate. Such salts are formed by procedures well known in the art.
Other acids such as oxalic acid, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining compounds of the invention and their pharmaceutically acceptable acid addition salts.
Halogen is fluorine, chlorine, bromine or iodine. Alkyl means a straight chain or branched chain of one to six carbon atoms, including but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, and hexyl; methyl, ethyl, propyl and isopropyl are preferred groups.
Cycloalkyl means cyclic alkyl of three to seven carbon atoms, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl;
Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.
Alkenyl means a group of from two to six carbon atoms, including at least one double bond, for example, but not limited to ethenyl, 1 ,2- or 2,3-propenyl, 1 ,2-, 2,3-, or 3,4-butenyl.
Alkynyl means a group of from two to six carbon atoms, including at least one triple bond, for example, but not limited to ethynyl, 1 ,2-, 2,3-propynyl, 1 ,2-, 2,3- or 3,4- butynyl.
Alkoxy is O-alkyl, wherein alkyl is as defined above.
Amino is NH2 or NH-alkyl or N-(alkyl)2, wherein alkyl is as defined above.
Heteroaryl is a 5- or 6-membered heterocyclic monocyclic group. Such a monocyclic heteroaryl group includes, for example, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, isoxazol-3- yl, isoxazol-4-yl, isoxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl, 1 ,2,4- thiadiazol-3-yl, 1 ,2,4-thiadiazol-5-yl, 1 ,2,5-oxadiazol-3-yl, 1 ,2,5-oxadiazol-4-yl, 1 ,2,5- thiadiazol-3-yl, 1 ,2,5-thiadiazol-4-yl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1 -pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 2- pyrazinyl, 1-pyrazolyl, 3-pyrazolyl and 4-pyrazolyl.
Aryl means an aromatic group such as phenyl or naphtyl. Aralkyl means arylalkyl wherein aryl and alkyl is as defined above, meaning for example benzyl or phenethyl.
I.p. means intraperetoneally, which is a well known route of administration.
P.O. means perorai, which is a well known route of administration.
Further, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
It will be appreciated by those skilled in the art that the compounds of the present invention contain several chiral centres and that such compounds exist in the form of isomers (i.e. enantiomers). The invention includes all such isomers and any mixtures thereof including racemic mixtures.
Some of the compounds of the present invention exist in (+) and (-) forms as well as in racemic forms. Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds ot the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallization of d- or I- (tartrates, mandelates, or camphorsulphonate) salts for example. The compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compounds of the present invention with an optically active chloroformate or the like.
Additional methods for the resolvation of optical isomers, known to those skilled in the art may be used, and will be apparent to the average worker skilled in the art. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981 ).
The compounds of the invention may be prepared in numerous ways. The compounds of the invention and their pharmaceutically acceptable derivatives may thus be prepared by any method known in the art for the preparation of compounds of analogous structure, and as shown in the representative examples which follow.
Biology
The compounds of the present invention are potent blockers of chloride channels in normal as well as sickle cell erythrocytes. The ability of the compounds to block the erythrocyte chloride channels could not be demonstrated by classical electrophysiological measurements such as patch clamping, since the channel unit conductance is below the detection limit of these techniques.
All dose-response experiments were therefore performed by concomitant measurements of conductive netfluxes of Cl" (JCι) and membrane potentials (Vm) in suspensions of erythrocytes (Bennekou, P. and Christophersen, P. (1986), Flux ratio of Valinomycin - Mediated K+ Fluxes across the Human Red Cell Membrane in the presence of the Protronophore CCCP. J. Membrane Biol. 93, 221-227. ). The membrane Cl'-conductances were calculated by the following equation (Hodgkin, A. L. and Huxley, A.F. (1952) The components of membrane conductance in the giant axon of loligo. J. Physiol. Lond. 116, 449-472):
F * Jcι Gα =
(Vm - Ec)
where F is the Faraday constant and Eci is the Nernst potential for the Cl-ion. Administration of N-(3-Trifluoromethylphenyl)-N'-(2-hydroxy-3-nitro-phenyl) urea to a suspension of normal erythrocytes blocked GCι more than 95 % with an IC50-value of 4 μM. The compound equipotently blocked Gα from oxygenated as well as deoxygenated homozygoteous sickle cell erythrocytes. Pharmaceutical compositions
While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.
The invention thus further provides pharmaceutical formulations comprising a compound of the invention or a pharmaceutically acceptable salt or derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
Pharmaceutical formulations include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub¬ cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
The compounds of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Formulations containing ten (10) milligrams of active ingredient or, more broadly, 0.1 to one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
The compounds of the present invention can be administrated in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as admixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
The compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
For topical administration to the epidermis the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
Formulations suitable for topical administration in the mouth include lozenges comprising active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.
Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve.
Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrroUdone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
In formulations intended for administration to the respiratory tract, including intranasal formulations, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. When desired, formulations adapted to give sustained release of the active ingredient may be employed.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
Tablets or capsules for oral administration and liquids for intravenous administration are preferred compositions.
Methods of treating
The compounds of the present invention are, due to their potent chloride channel blocking activity, useful in the treatment of sickle cell anaemia, brain oedema following ischaemia or tumors, diahreea, and hypertension (diuretic) as well as other disorders responsive to the blockade of chloride channels. The compounds of the invention may also be useful in the treatment of allergic and inflammatory conditions, for the promotion of wound healing and the treatment of ulcers. The compounds of the present invention may accordingly be administered to a living animal body, including a human, in need of treatment, alleviation, or elimination of an indication associated with or responsive to chloride channel blocking activity. This includes especially sickle cell anaemia, brain oedema following ischaemia or tumors, diahreea, and hypertension (diuretic).
Suitable dosage range are 0.1-500 milligrams daily, and especially 10-70 milligrams daily, administered once or twice a day, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge. The following examples will illustrate the invention further, however, they are not to be construed as limiting.
EXAMPLE 1
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-nitrophenyl) urea
2-hydroxy-5-nitroaniline (1.25 g, 8.1 mmol) and 3-(trifluoromethyl)phenyl isocyanate (1.00 ml, 7.3 mmol) were added to toluene (50 ml). The reaction mixture was stirred at RT overnight, the product filtered off and recrystallized from methanol/water 8:1 (45 ml). 1.39 g (56%) of the title compound was isolated. M.p. 226°C (dec).
The following compounds were prepared in a similar manner:
N-(3-(trifluoromethyl)phenyl)-N'-(2, 5-dimethoxyphenyl) urea, N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-4-(phenylamino)phenyl) urea, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-4-nitrophenyl) urea. M.p. 199-200°C, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl) urea. M.p. 171-173°C, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-tert-butylphenyl) urea. M.p. 173-174°C, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-methoxyphenyl) urea. M.p. 153-154°C, N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-5-(trifluoromethyl)phenyl) urea. M.p. 192- 194°C,
N-(3-(trifluoromethyl)phenyl)-N'-(3-hydroxy-2-naphthyl) urea. M.p. 184-188°C (dec), N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-1-naphthyl) urea. M.p. 187-189°C (dec), N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-5-chlorophenyl) urea. M.p. 169-171 °C, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-6-nitrophenyl) urea. M.p. 174-175°C, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxyphenyl) urea. M.p. 178-179°C, N-(3-(trifluoromethyl)phenyl)-N'-(2, 5-dimethoxy-4-nitrophenyl) urea, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-3-nitrophenyl) urea. M.p. 223-224°C, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-4-chlorophenyl) urea. M.p. 173-174°C, N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-5-methoxycarbonyl-4-nitrophenyl) urea, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chloro-4-nitrophenyl) urea. M.p. 201- 203°C,
N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-5-methoxycarbonylphenyl) urea, N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-4-nitro-5-carboxyphenyl) urea. EXAMPLE 2
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-4-aminophenyl) urea.
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-4-nitrophenyl) urea (1.00 g, 2.9 mmol) was subjected to catalytic reduction in tetrahydrofuran (50 ml) using 5% palladium on carbon (0.20 g). The reaction mixture was filtered through a path of celite. Evaporation of the filtrate and subsequent recrystallization of the crude product from methanol/water 1 :1 (50 ml) afforded the title compound. 0.68 g (75%) of the title compound was isolated. M.p. 200-202°C.
EXAMPLE 3
N-(1 -naphthyl)-N'-(2-hydroxy-5-(trifluoromethyl)phenyl) urea.
2-hydroxy-5-(trifluoromethyl)aniline (0.12 g, 0.7 mmol) in toluene (3 ml) was added to a solution of alpha-naphthyl isocyanate (0.11 g, 0.7 mmol) in toluene (3 ml). The reaction was stirred at RT overnight and the product filtered off. 0.17 g (72%) of the title compound was isolated. M.p. 205-207°C.
EXAMPLE 4
N-(2-methoxy-5-chlorophenyl)-3-(trifluoromethyl)phenylacetic amide.
Dicyclohexylcarbodiimide (2.20 g, 10.7 mmol) was added to a solution of 3- (trifluoromethyl)phenylacetic acid (2.00 g, 9.8 mmol) and 5-chloro-2-methoxyaniline (1.55 g, 9.8 mmol) in dichloromethane (50 ml). The reaction was stirred at RT overnight. The reaction mixture was filtered and the filtrate evaporated to dryness. The residue was recrystallized from methanol/water 2:1 (30 ml). 2.05 g (61%) of the title compound was isolated.
The following compound was prepared in a similar manner.
N-(3-(trifluoromethyl)phenyl)-2-methoxy-5-chlorophenylacetic amide starting from 3- trifluoromethylphenylamine and 2-methoxy-5-chlorophenylacetic acid. EXAMPLE 5
N-(3,5-dichlorophenyl)-N'-(2-methoxy-5-(trifluoromethyl)phenyl) urea
3,5-dichlorophenyl isocyanate (0.94 g, 5.0 mmol) in toluene (10 ml) was added to a solution of 2-methoxy-5-(trifluoromethyl)aniline (0.96 g, 5.0 mmol) in toluene (10 ml). The reaction was stirred at RT for 1 hour and the product filtered off. 1.20 (63%) of the title compound was isolated.
EXAMPLE 6
N-(5,6,7,8-tetrahydro-1-naphthyl)-N'-(2-methoxy-5-(trifluoromethyl)phenyl) urea.
2-methoxy-5-(trifluoromethyl)phenyl carbamoylchloride (0.81 g, 3.2 mmol), 1-amino- 5,6,7,8-tetrahydronaphtalene (445 ml, 3.2 mmol) and triethylamine (446 ml, 3.2 mmol) were added to chloroform (20 ml) and the resulting mixture was stirred at RT overnight. The reaction mixture was poured into water and extracted with ethyl acetate. The solvent was evaporated in vacuuo and the residue recrystallized from toluene (20 ml). 0.45 g of the title compound was isolated.
EXAMPLE 7
N-(3-(trlfluoromethyl)phenyl)-N'-(2-methoxy-5-(trifluoromethyl)phenyl) thiourea.
3-(trifluoromethyl)phenyl isothiocyanate in toluene (0.76 ml, 5.0 mmol) was added to a solution of 2-methoxy-5-(trifluoromethyl)aniline in toluene (10 ml). The resulting reaction mixture was stirred at RT overnight and the product was subsequently filtered off. 1.00 g (51%) of the title compound was isolated.
The following compound was prepared in a similar manner. N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-5-chlorophenyl) thiourea. EXAMPLE 8
N-(3-methoxycarbonylphenyl)-N'-(2-methoxy-5-chlorophenyl) urea.
N-(3-carboxyphenyl)-N'-(2-methoxy-5-chlorophenyl) urea (3.00 g, 9.4 mmol) was suspended in methanol (100 ml). Concentrated sulfuric acid (1.0 ml) was added and the reaction was heated at reflux for 6 hours. The reaction mixture was poured into cold (0°C) water (600 ml). Filtration of the suspension afforded the crude product. The crude product was purified by column chromatography on silica using dichloromethane/ethyl acetate 19:1 as eluent. 2.35 g of the title compound was isolated.
EXAMPLE 9
1-(3-(trifluoromethyl)phenyl-3-(2-methoxy-5-chlorophenyl) guanidine.
A mixture of 3-(trifluoromethyl)phenylcyanamide (2.00 g, 10.7 mmol) and 5-chloro-2- methoxyaniline hydrochloride (2.30 g, 11.8 mmol) was suspended in acetonitrile (80 ml). The reaction was heated at reflux for four days. The solvent was evaporated in vacuo. The residue was redissolved in dichloromethane (100 ml) and washed with a saturated sodium bicarbonate solution. The crude product was purified by column chromatography on silica gel initially using dichloromethane as eluent followed by dichloromethane/methanol 9:1 as eluent. 2.27 g of the title compound was obtained as a dark oil which slowly crystallises.
EXAMPLE 10
N-(3-benzoylphenyl)-N'-(2-methoxy-5-chlorophenyl) urea.
A mixture of 5-chloro-2-methoxyphenyl isocyanate (1.00 g, 5.4 mmol) and 3- aminobenzophenone (1.29 g, 6.5 mmol) was stirred in toluene (20 ml) for two days. The reaction was filtered and the filter cake washed with toluene. 1.9 g of the title compound was isolated.
The following compounds were prepared in a similar manner. N-(3-carbamoylphenyl)-N'-(2-methoxy-5-chlorophenyl) urea, N-(3-(trifluoromethoxy)phenyl)-N'-(2-methoxy-5-chlorophenyl) urea, N-(3-methylphenyl)-N'-(2-methoxy-5-chlorophenyl) urea, N-(3-hydroxyphenyl)-N'-(2-methoxy-5-chlorophenyl) urea, N-(3-nitrophenyl)-N'-(2-methoxy-5-chlorophenyl) urea, and N-(3-carboxyphenyl)-N'-(2-methoxy-5-chlorophenyl) urea.
EXAMPLE 11
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-4-(phenylamino)phenyl) urea
To a cold (0°C) suspension of N-(3-(trifluoromethyl)phenyl)-N'-(2-methoxy-4- (phenylamino)phenyl) urea (1.00 g, 2.5 mmol) in dichloromethane (50 ml), boron tribromide (0.48 ml, 5.1 mmol) was added. After the addition of boron tribromide the ice bath was removed and the reaction mixture was stirred for 3 hours at RT. The reaction was poured on ice (10 ml) and 1 M sodium bicarbonate (50 ml) was added. The aqueous phase was extracted with ethyl acetate (50 ml) and the organic phase dried over magnesium sulfate. 1.05 g crude product was obtained. The crude product was purified by column chromatography on silica gel using petroleum ether/ethyl acetate 1 :1 as eluent. The partly purified product (0.61 g) was recrystallized from ethanol/water 1 :1 (20 ml). 0.20 g (21%) of the title compound was isolated. M.p. 166- 168°C.
The following compounds were prepared in a similar manner.
N-(3-(trifluoromethyl)phenyl)-N'-(2, 5-dihydroxyphenyl) urea, M.p. 165-168°C, N-(3-(trifluoromethyl)phenyI)-N'-(2-hydroxy-5-(trifluoromethyl)phenyl) urea, M.p. 160- 162°C,
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorobenzyl) urea, M.p. 56-66°C, N-(3-(trifluoromethyl)phenyl)-N'-(2,3-dihydroxybenzyl) urea, M.p. 159-161 °C, N-(2-hydroxy-5-chlorophenyl)-3-(trifluoromethyl)phenylacetic amide, M.p. 148-153°C, N-(3, 5-dichlorophenyl)-N'-(2-hydroxy-5-(trifluoromethyl)phenyl) urea, M.p. 202°C, N-(5,6,7,8-tetrahydro-1-naphthyl)-N'-(2-hydroxy-5-(trifluoromethyl)phenyl) urea, N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-(trifluoromethyl)phenyl) thiourea, M.p.
124-125°C,
N-(3-methylphenyl)-N'-(2-hydroxy-5-chlorophenyl) urea, M.p. 179-180°C,
N-(3-hydroxyphenyl)-N'-(2-hydroxy-5-chlorophenyl) urea,
N-(3-nitrophenyl)-N*-(2-hydroxy-5-chlorophenyl) urea, M.p. 194-196°C,
N-(3-benzoylphenyl)-N*-(2-hydroxy-5-chlorophenyl) urea, M.p. 205-206°C,
N-(3-(trifluoromethoxy)phenyl)-N'-(2-hydroxy-5-chlorophenyl) urea, M.p. 158-159°C,
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-methoxy-4-nitrophenyl) urea, M.p. 220-
222°C,
N-(3-(trifluoromethyl)phenyl)-N'-(2, 4-dihydroxyphenyl) urea, M.p. 179-180°C,
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-4-methoxyphenyl) urea, M.p. 176-177°C,
N-(3-(trifluoromethyl)phenyl)-N'-(2-hydroxy-5-chlorophenyl) thiourea,
1-(3-(trifluoromethyl)phenyl-3-(2-hydroxy-5-chlorophenyl) guanidine, M.p. 172-174°C, and
N-(3-(trifluoromethyl)phenyl)-2-hydroxy-5-chlorophenylacetic amide, M.p. 148-150°C.

Claims

We Claim:
1. The use of a compound having the formula
or a pharmaceutically acceptable salt thereof
wherein
R2, R3, R4 and R5 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl and heteroaryl groups may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or R3and R4 or R4 and R5 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R2, R3, R4 and R5 is as defined above;
Y is -CO-, -CS-, -SO2-, or -C(=N-R8)-, wherein R8 is hydrogen, alkyl, or cyano;
X is -NH-, -CH2-NH-, -SO2-NH-, or CH2;
Z is -NR6-, -O-, -CH=CH-, -N=CH-, -CH=N-, or -NR6-CH2-; wherein R6 is hydrogen, or alkyl;
and
R11, R12, R13, R14 and R15 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalky, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or one of R11 and R12, R12 and R13, R13and R14or R14 and R15 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R11, R12, R13, R14and R15 is as defined above, for the preparation of a medicament for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels.
2. The use of a compound according to claim 1 for the preparation of a medicament for the treatment of sickle-cell anaemia, brain oedema following ischaemia, or tumours, diahreea, hypertension (diuretic) and glaucoma.
3. The use of a compound according to claim 1 for the preparation of a medicament for the treatment of allergic or inflammatory conditions and ulcers.
4. A method for the treatment of a disorder or disease of a living animal body, including a human, which disorder or disease is responsive to the blockade of chloride channels, comprising administering to a living animal body in need thereof a therapeutically effective amount of a compound having the formula
or a pharmaceutically acceptable salt thereof
wherein
R2, R3, R4 and R5 are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy; cyano, nitro and amino; or R3and R4 or R4 and R5 together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R2, R3, R4 and R5 is as defined above;
Y is -CO-, -CS-, -SO2-, or -C(=N-R8)-, wherein R8 is hydrogen, alkyl, or cyano;
X is -NH-, -CH2-NH-, -SO2-NH-, or -CH2-;
Z is -NR6-, -O-, -CH=CH-, -N=CH-, -CH=N-, or -NR6-CH2-, wherein R6 is hydrogen, or alkyl;
R11, R12, R13, R14 and R15are each independently selected from hydrogen; alkyl; cycloalkyl; cycloalkylalkyl; alkenyl; alkynyl; alkoxy; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; amino; and aryl, aralkyl, arylamino, aryloxy, aryl-CO-, or heteroaryl, wherein the aryl or heteroaryl group may be substituted one or more times with substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, hydroxy, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino; or one of R11 and R12, R12 and R13, R13 and R14or R14 and R15together form a fused 4 to 7 membered carbocyclic ring which may be unsaturated, or partially or fully saturated while the other substituents R11, R12, R13, R14 and R15 is as defined above.
5. A method for the treatment of a disorder or disease of a living animal body which disorder or disease is sickle-cell anaemia, brain oedema following ischaemia, or tumours, diahreea, hypertension (diuretic) or glaucoma comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a compound according to claim 4.
6. A method for the treatment of a disorder or disease of a living animal body which disorder or disease is allergic or inflammatory conditions or ulcers comprising administering to a living animal body, including a human, in need thereof a therapeutically effective amount of a compound according to claim 4.
EP97924020A 1996-05-24 1997-05-26 Phenyl derivatives useful as blockers of chloride channels Withdrawn EP0910358A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK60296 1996-05-24
DK60296 1996-05-24
PCT/EP1997/002724 WO1997045111A1 (en) 1996-05-24 1997-05-26 Phenyl derivatives useful as blockers of chloride channels

Publications (1)

Publication Number Publication Date
EP0910358A1 true EP0910358A1 (en) 1999-04-28

Family

ID=8095440

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97924020A Withdrawn EP0910358A1 (en) 1996-05-24 1997-05-26 Phenyl derivatives useful as blockers of chloride channels

Country Status (4)

Country Link
EP (1) EP0910358A1 (en)
JP (1) JP2000510862A (en)
AU (1) AU2962297A (en)
WO (1) WO1997045111A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281240B1 (en) * 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
US6696475B2 (en) 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
NZ337976A (en) * 1997-04-22 2001-05-25 Neurosearch As Substituted phenyl derivatives, their preparation and use
AU8534198A (en) * 1997-08-05 1999-03-01 Novo Nordisk A/S Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use
EP1361874A1 (en) * 2001-02-15 2003-11-19 Neurosearch A/S Treatment of diseases characterized by excessive or insufficient cell death
DE60328202D1 (en) * 2002-09-05 2009-08-13 Neurosearch As DIARYL HARVEST DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
JP2006507329A (en) 2002-11-21 2006-03-02 ニューロサーチ、アクティーゼルスカブ Novel arylureidobenzoic acid derivatives and uses thereof
EA009732B1 (en) 2003-07-22 2008-02-28 Арена Фармасьютикалз, Инк. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-htserotonin receptor useful for the prophylaxis and treatment of disorders related thereto
CN1845726A (en) 2003-09-04 2006-10-11 波塞东医药公司 Erg channel openers for the treatment of cardiac arrhythmias
WO2005040100A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
CN1926114B (en) 2004-03-23 2011-08-24 艾尼纳制药公司 Processes for preparing substituted N-aryl-N'-[3-(1H-pyrazol-5-yl) phenyl] ureas and intermediates thereof
CN1926098A (en) * 2004-03-29 2007-03-07 神经研究公司 Novel urea derivatives and their medical use
PE20061130A1 (en) 2004-11-19 2007-01-05 Arena Pharm Inc 3-PHENYL-PIRAZOLE DERIVATIVES AS MODULATORS OF THE SEROTONIN 5-HT2A RECEPTOR
EP2018371B1 (en) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
EP3395816A1 (en) 2006-05-18 2018-10-31 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
TWI415845B (en) 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP5393677B2 (en) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド Imidazo [1,2-a] pyridine derivatives as modulators of 5-HT2A serotonin receptors for the treatment of disorders associated with 5-HT2A serotonin receptors
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8637575B2 (en) 2008-06-05 2014-01-28 Novotyr Therapeutics Ltd. Modulators of protein kinase signaling
US9034911B2 (en) 2008-10-28 2015-05-19 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US8618145B2 (en) 2009-05-12 2013-12-31 Mei Han Small molecular compounds capable of accelerating proliferation of stem cells and use thereof
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2654428B1 (en) * 2010-12-22 2018-02-14 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and usese thereof
WO2015008206A1 (en) 2013-07-14 2015-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
JP2018504418A (en) 2015-02-05 2018-02-15 ティルノーヴォ リミテッド Combination of an IRS / STAT3 dual modifier and an anticancer agent for the treatment of cancer
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
BR112018000728A2 (en) 2015-07-15 2018-09-04 Axovant Sciences Gmbh method for the prophylaxis and / or treatment of visual hallucinations in a subject in need
AR101498A1 (en) * 2015-08-11 2016-12-21 Chemo Res S L PROCEDURE FOR THE PREPARATION OF COMPOUND N- (3,5-DIMETHYLPHENYL) -N- (2-TRIFLUOROMETILFENIL) GUANIDINE AND ITS CRYSTALLINE FORM A
CA3194203A1 (en) * 2020-09-14 2022-03-17 Genzyme Corporation Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234922A (en) * 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
DK41193D0 (en) * 1993-04-07 1993-04-07 Neurosearch As ion channel openers
DE69534632T2 (en) * 1994-09-16 2006-06-14 Childrens Medical Center Clotrimazole metabolites in the treatment of sickle cell disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9745111A1 *

Also Published As

Publication number Publication date
AU2962297A (en) 1998-01-05
WO1997045111A1 (en) 1997-12-04
JP2000510862A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
US6417393B1 (en) Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
WO1997045111A1 (en) Phenyl derivatives useful as blockers of chloride channels
AU728520B2 (en) Substituted phenyl derivatives, their preparation and use
EP0693053B1 (en) Urea and amide derivatives and their use in the control of cell membrane potassium channels
US6706749B2 (en) Substituted phenyl derivatives, their preparation and use
US6696475B2 (en) Substituted phenyl derivatives, their preparation and use
US6413996B2 (en) Diaminocyclobutene-3,4-dione derivatives, their preparation and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUROSEARCH A/S

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001201